Items tagged with Guidelines
ECDC revised the tuberculosis section in its Risk Assessment Guidelines for Infectious Diseases Transmitted on Aircraft (RAGIDA). The new guidelines include an updated systematic review on TB transmission on aircraft, which concludes that there is still not enough evidence of the effectiveness of identifying, tracing and investigating the passengers that might have been infected during a flight.
11 July 2014 ¦ Geneva - Failure to provide adequate HIV services for key groups – men who have sex with men, people in prison, people who inject drugs, sex workers and transgender people – threatens global progress on the HIV response, warns WHO.
The Checklist focuses on primary and secondary health-care facilitie and is a tool for protecting spread of TB to patients and health-care workers. The Checklist will be included in the WHO Consolidated Guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection.
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries (post)
U.S. Preventive Services Task Force issues draft recommendation statement on screening for latent tuberculosis infection (post)
Task Force recommends screening adults at increased risk
The World Health Organization (WHO)'s Global TB Program has released Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions.
The European Medicines Agency (EMA) has launched a public consultation on revised guidance on the development of new medicines to treat tuberculosis (TB). The guidance is an addendum to EMA’s guideline on the evaluation of medicines to treat bacterial infections.
Asymptomatic adults at higher risk for latent tuberculosis infection (LTBI) should be screened in primary care settings, advises a new recommendation statement from the US Preventive Services Task Force (USPSTF).
The European Medicines Agency (EMA) is organising a workshop on the development of new medicines to treat tuberculosis (TB). The event will take place at EMA’s premises in London on 25 November 2016, from 9:00 to 16:00.
WHO: The use of delamanid in the treatment of MDR-TB in children and adolescents: Interim policy guidance (post)
Multidrug-resistant tuberculosis (MDR-TB) is a public health challenge of growing concern. Approximately 580 000 people acquired MDR-TB in 2015, with children accounting for close to 30 000 of MDR-TB cases.
Page 1 of 6 · Total posts: 01 2 Last→